Attune Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel once-daily small molecule therapeutics for treatment of rare diseases. Attune Pharmaceuticals is currently advancing two programs, one in Hereditary Angioedema (HAE) and a second in complement-mediated diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/24/19 | $23,000,000 | Series B |
Boxer Capital LifeSci Venture Partners RA Capital RTW Investments Tang Capital Venrock Healthcare Partners  | undisclosed |
